Answers are grounded in this paper and cite their sources.
ZUMA-5 was the pivotal phase II single-arm trial (NCT03105336) that evaluated the efficacy and safety of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell thera...
No takes yet. Share an insight, caveat, or question.
Gribben et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: